534 active not recruiting. 534 Phase 2, 130 Phase 1, 9 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 534 | Active not recruiting 534 |
| Phase 1 | 130 | Active not recruiting 130 |
| Phase 3 | 9 | Active not recruiting 9 |
Follow Lymphoproliferative Disorders: new trials by email Literature Review of Lymphoproliferative Disorders trials Research Report on Lymphoproliferative Disorders
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| PET/CT-Guided Maintenance Therapy in Previously Untreated MZL Orelabrutinib - Marginal Zone Lymphoma(MZL) | Phase 2 | Active not recruiting | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | 45 | 2026-05-14 | 2026-11-04 |
| Study to Assess Change in Disease Activity of Oral Venetoclax in Adult Participants With Recurring Relapsed or Refractory (R/R) Waldenström Macroglobulinemia (WM)/Lymphoplasmacytic Lymphoma (LPL) Venetoclax - Waldenstrom Macroglobulinemia, Lymphoplasmacytic Lymphoma | Phase 2 | Active not recruiting | AbbVie | 14 | 2026-03-17 | 2026-09-09 |
| A Study of JNJ-79635322 in Participants With Relapsed or Refractory Multiple Myeloma JNJ-79635322 - Multiple Myeloma | Phase 2 | Active not recruiting | Janssen Research & Development, LLC | 168 | 2026-02-08 | 2026-11-03 |
| A Phase 1b/2 Study to Assess the Safety and Efficacy of Subcutaneous Blinatumomab in Combination With Low Intensity Chemotherapy in Older Patients With Newly Diagnosed B-Cell Acute Lymphoblastic Leukemia Blinatumomab, Mini-CVD, MTX/ARA-C - B-cell Acute Lymphoblastic Leukemia | Phase 1 / Phase 2 | Active not recruiting | M.D. Anderson Cancer Center | 3 | 2026-01-30 | 2026-08-18 |
| Efficacy and Safety of Glofitamab Combined With GemOxin the Treatment of Refractory Diffuse Large B-Cell Lymphoma Glofitamab, Gemcitabin, Oxaliplatin - Refractory Diffuse Large B-Cell Lymphoma (DLBCL) | Phase 2 | Active not recruiting | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | 40 | 2026-01-01 | 2026-03-18 |
| Efficacy and Safety of Sequential Autologous Hematopoietic Stem Cell Transplantation Combined With Tafasitamab, Lenalidomide, and Standard Immunochemotherapy for Relapsed/Refractory Diffuse Large B-cell Lymphoma Treatment with the Tafa+Len+ standard immunotherapy regimen (e.g., R-ICE, R-DHAP, R-GDP, etc.) - Relapsed/Refractory Diffuse Large B Cell Lymphoma | Phase 2 | Active not recruiting | The First Affiliated Hospital of Soochow University | 25 | 2026-01-01 | 2026-06-02 |
| A Study of Subcutaneous Blinatumomab in Children With R/R and and MRD+ B-Cell Precursor Acute Lymphoblastic Leukemia Blinatumomab - Relapsed/Refractory B-Cell Precursor Acute Lymphoblastic Leukemia, Minimal Residual Disease + B-Cell Acute Lymphoblastic Leukemia | Phase 1 / Phase 2 | Active not recruiting | Amgen | 104 | 2025-12-08 | 2026-10-05 |
| Ulcer Plants: Highly Accessible Plant Antiseptics for Use in Remote Areas of PNG - Second Trial Ficus septica exudate, Active Comparator: Savlon antiseptic cream (cetrimide with chlorhexidine digluconate) - Cutaneous Ulcer Disease, Skin Sores | Phase 2 | Active not recruiting | Fundación FLS de Lucha Contra el Sida, las Enfermedades Infecciosas y la Promoción de la Salud y la Ciencia | 222 | 2025-11-03 | 2026-07-16 |
| Pemigatinib in Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphomas Pemigatinib - Relapsed or Refractory B-cell Non-Hodgkin Lymphoma, Mantle Cell Lymphoma | Phase 2 | Active not recruiting | University of Utah | 1 | 2025-10-03 | 2026-07-09 |
| Treatment of Orelabrutinib+Hi-CVP Regimen for Previously Untreated MZL Orelabrutinib, Zuberitamab, Cyclophosphamide - Marginal Zone Lymphoma(MZL) | Phase 2 | Active not recruiting | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | 65 | 2025-10-01 | 2026-04-02 |
| Orelabrutinib Plus Low-Dose Radiotherapy Or Rituximab For Ocular Adnexal MALT Lymphoma Orelabrutinib (ICP-022), radiotherapy, Rituximab (R) - Marginal Zone Lymphoma of Ocular Adnexal, Marginal Zone Lymphoma(MZL) | Phase 2 | Active not recruiting | Second Affiliated Hospital, Zhejiang University, School of Medicine | 39 | 2025-09-19 | 2025-11-25 |
| JS203 Combination Regimens in B-Cell Non-Hodgkin's Lymphoma JS203 in combination with gemcitabine and oxaliplatin, JS203 in combination with ifosfamide, carboplatin and etoposide, JS203 in combination with rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone - B-cell Non-Hodgkin's Lymphoma | Phase 2 | Active not recruiting | Shanghai Junshi Bioscience Co., Ltd. | 180 | 2025-08-17 | 2026-09-04 |
| Long-Term Safety of Pirtobrutinib in Participants With Previously Treated Types of Blood Cancers Pirtobrutinib - Lymphoma, Non-Hodgkin, Leukemia, Lymphocytic, Chronic, B-Cell | Phase 2 | Active not recruiting | Eli Lilly and Company | 13 | 2025-08-07 | 2026-04-17 |
| A Phase II Trial of Teclistamab in Participants With Previously Treated Immunoglobulin Light-chain (AL) Amyloidosis Teclistamab - AL Amyloidosis | Phase 2 | Active not recruiting | European Myeloma Network B.V. | 30 | 2025-07-02 | 2026-07-20 |
| Blinatumomab Combined With Venetoclax as Maintenance Therapy After Allo-HSCT in High-risk Ph Negative Acute B-cell Lymphoblastic Leukemia blinatumomab combined with venetoclax as maintenance therapy - B-Cell Acute Lymphoblastic Leukemia, Adult | Phase 2 | Active not recruiting | Zhejiang University | 24 | 2025-06-01 | 2025-09-30 |
| Study of Targeted CD22/CD19 CAR-T Therapy for First-line Consolidation of B-cell Lymphoma CD22/CD19 CAR-T cell immunotherapy - Lymphoma | Phase 2 | Active not recruiting | Daihong Liu | 50 | 2025-04-01 | 2025-07-30 |
| Psilocybin in the Treatment of Cannabis Use Disorder: A-Proof-of-Concept Study Psilocybin combined with Psychotherapy - Cannabis Use Disorder, Moderate, Cannabis Use Disorder, Severe | Phase 2 | Active not recruiting | McMaster University | 16 | 2025-03-21 | 2026-08-31 |
| A Study of Cobolimab Plus Dostarlimab in Pediatric and Young Adult Participants With Cancer Cobolimab, Dostarlimab - Melanoma, Hodgkin Lymphoma | Phase 1 / Phase 2 | Active not recruiting | GlaxoSmithKline | 83 | 2025-03-06 | 2025-11-12 |
| Nivolumab in Multiple Myeloma Patients After Idecabtagene Vicleucel Nivolumab - Multiple Myeloma | Phase 2 | Active not recruiting | Wake Forest University Health Sciences | 1 | 2025-02-28 | 2026-07-13 |
| GATE1: A Multicenter Phase II Study of Pirtobrutinib, Rituximab and Venetoclax Combination Therapy for Patients With Previously Untreated Mantle Cell Lymphoma Pirtobrutinib, Rituximab, Venetoclax - Mantle Cell Lymphoma | Phase 2 | Active not recruiting | M.D. Anderson Cancer Center | 50 | 2025-01-30 | 2026-11-02 |
Showing 20 of 534. Sign in to see all of them.
Multiple Myeloma (144) · Lymphoma (81) · Leukemia, Lymphocytic, Chronic, B-Cell (66) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (63) · Lymphoma, Non-Hodgkin (57) · Lymphoma, Large B-Cell, Diffuse (56) · Lymphoma, Mantle-Cell (50) · Lymphoma, Follicular (48) · Recurrence (39) · Hodgkin Disease (32) · Lymphoma, B-Cell (32) · Lymphoma, B-Cell, Marginal Zone (31) · Leukemia (27) · Leukemia, Myeloid, Acute (26) · Hematologic Neoplasms (25)
Hemic and Lymphatic Diseases (527) · Immune System Diseases (527) · Immunoproliferative Disorders (525) · Neoplasms by Histologic Type (518) · Neoplasms (499) · Lymphatic Diseases (416) · Hematologic Diseases (299) · Lymphoma (224) · Lymphoma, Non-Hodgkin (170) · Paraproteinemias (162) · Cardiovascular Diseases (160) · Vascular Diseases (160) · Neoplasms, Plasma Cell (158) · Hemorrhagic Disorders (157)
Cyclophosphamide (92) · Rituximab (86) · Dexamethasone (81) · Lenalidomide (67) · Doxorubicin (50) · venetoclax (47) · Specimen Handling (42) · Biopsy (41) · Prednisone (41) · Vincristine (41) · daratumumab (39) · acalabrutinib (35) · ibrutinib (35) · Magnetic Resonance Spectroscopy (34) · Calcium Dobesilate (33)
National Cancer Institute (NCI) (63) · M.D. Anderson Cancer Center (40) · Memorial Sloan Kettering Cancer Center (32) · City of Hope Medical Center (23) · St. Jude Children's Research Hospital (11) · Dana-Farber Cancer Institute (10) · Genmab (7) · GlaxoSmithKline (7) · Hoffmann-La Roche (7) · Institute of Hematology & Blood Diseases Hospital, China (7) · Janssen Research & Development, LLC (7) · University of Washington (7) · Weill Medical College of Cornell University (7) · AbbVie (6) · Acerta Pharma BV (6)
United States (390) · Spain (67) · France (66) · Italy (61) · China (58) · Canada (55) · Australia (44) · United Kingdom (43) · Germany (40) · Belgium (29) · Netherlands (28) · South Korea (26) · Japan (25) · Poland (23) · Denmark (21)
Alex F Herrera (5) · Alison Moskowitz, MD (5) · Christian Buske, MD (4) · David S Hong (3) · Elias Jabbour (3) · Filip Janku (3)
PMID 41671463, PMID 33357481, PMID 39319495, PMID 40550489, PMID 31401903, PMID 34515338, PMID 27503501, PMID 28714866, PMID 34182226, PMID 34398557, PMID 34608724, PMID 34797699, PMID 35285981, PMID 35622074, PMID 37505794, PMID 39563886, PMID 40135712, PMID 40226119, PMID 40472301, PMID 42411504, PMID 42541678, PMID 10552938, PMID 15486066, PMID 20385792, PMID 20516455, PMID 21487108, PMID 22225488, PMID 22285199, PMID 22940833, PMID 24174627, PMID 24327518, PMID 24659631, PMID 24699307, PMID 25331113, PMID 25555420, PMID 25824111, PMID 26182309, PMID 26337493, PMID 26430171, PMID 26432046, PMID 26586415, PMID 26640039, PMID 26641137, PMID 26729345, PMID 26907630, PMID 26982511, PMID 27118452, PMID 27424289, PMID 27601462, PMID 27760761
2023 (36), U10CA180820 (34), U24CA196172 (18), P30CA033572 (15), 2019 (12), 2017 (10), U10CA180886 (10), 2018 (6), 2014 (5), U10CA180888 (5), 2015 (4), 2016 (3), P30CA015083 (3), U10CA180821 (3), P30CA015704 (2)